Selected research
Market Structure
Global Pulmonary Embolism Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Pulmonary Embolism Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Pulmonary Embolism Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Pulmonary Embolism Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Pulmonary Embolism Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Pulmonary Embolism Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Pulmonary Embolism Therapeutics include Johnson & Johnson, F. Hoffmann-La Roche, Daiichi Sankyo, Bristol-Myers Squibb and Boehringer Ingelheim International, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Pulmonary Embolism Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Pulmonary Embolism Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Pulmonary Embolism Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Pulmonary Embolism Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.
Pulmonary Embolism Therapeutics Segment by Company
Johnson & Johnson
F. Hoffmann-La Roche
Daiichi Sankyo
Bristol-Myers Squibb
Boehringer Ingelheim International
Pulmonary Embolism Therapeutics Segment by Type
Oral
Parenteral
Pulmonary Embolism Therapeutics Segment by Application
Adult
Child
Pulmonary Embolism Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Embolism Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Embolism Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Embolism Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Pulmonary Embolism Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pulmonary Embolism Therapeutics industry.
Chapter 3: Detailed analysis of Pulmonary Embolism Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pulmonary Embolism Therapeuticsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Parenteral
Applications
- Adult
- Child
Companies covered
- Johnson & Johnson
- F. Hoffmann-La Roche
- Daiichi Sankyo
- Bristol-Myers Squibb
- Boehringer Ingelheim International
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Pulmonary Embolism Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Oral
- 1.2.3 Parenteral
- 1.3 Market Analysis by Application
- 1.3.1 Global Pulmonary Embolism Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Adult
- 1.3.3 Child
- 1.4 Global Market Growth Prospects
- 1.5 Global Pulmonary Embolism Therapeutics Growth Trends by Region
- 1.5.1 Global Pulmonary Embolism Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Pulmonary Embolism Therapeutics Market Size by Region (2021-2026)
- 1.5.3 Pulmonary Embolism Therapeutics Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Pulmonary Embolism Therapeutics Market Dynamics
- 2.1 Pulmonary Embolism Therapeutics Industry Trends
- 2.2 Pulmonary Embolism Therapeutics Industry Drivers
- 2.3 Pulmonary Embolism Therapeutics Industry Opportunities and Challenges
- 2.4 Pulmonary Embolism Therapeutics Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Pulmonary Embolism Therapeutics Revenue by Company (2021-2026)
- 3.2 Global Pulmonary Embolism Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Pulmonary Embolism Therapeutics Key Company Head office and Area Served
- 3.4 Global Pulmonary Embolism Therapeutics Company, Product Type & Application
- 3.5 Global Pulmonary Embolism Therapeutics Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Pulmonary Embolism Therapeutics Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Pulmonary Embolism Therapeutics Players Market Share by Revenue in 2025
- 3.6.3 2025 Pulmonary Embolism Therapeutics Tier 1, Tier 2, and Tier 3
4 Pulmonary Embolism Therapeutics Market by Type
- 4.1 Global Pulmonary Embolism Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Pulmonary Embolism Therapeutics Market Size by Type (2021-2032)
- 4.3 Global Pulmonary Embolism Therapeutics Market Size Share by Type (2021-2032)
5 Pulmonary Embolism Therapeutics Market by Application
- 5.1 Global Pulmonary Embolism Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Pulmonary Embolism Therapeutics Market Size by Application (2021-2032)
- 5.3 Global Pulmonary Embolism Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Johnson & Johnson
- 6.1.1 Johnson & Johnson Company Information
- 6.1.2 Johnson & Johnson Business Overview
- 6.1.3 Johnson & Johnson Pulmonary Embolism Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Johnson & Johnson Pulmonary Embolism Therapeutics Product Portfolio
- 6.1.5 Johnson & Johnson Recent Developments
- 6.2 F. Hoffmann-La Roche
- 6.2.1 F. Hoffmann-La Roche Company Information
- 6.2.2 F. Hoffmann-La Roche Business Overview
- 6.2.3 F. Hoffmann-La Roche Pulmonary Embolism Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 F. Hoffmann-La Roche Pulmonary Embolism Therapeutics Product Portfolio
- 6.2.5 F. Hoffmann-La Roche Recent Developments
- 6.3 Daiichi Sankyo
- 6.3.1 Daiichi Sankyo Company Information
- 6.3.2 Daiichi Sankyo Business Overview
- 6.3.3 Daiichi Sankyo Pulmonary Embolism Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Daiichi Sankyo Pulmonary Embolism Therapeutics Product Portfolio
- 6.3.5 Daiichi Sankyo Recent Developments
- 6.4 Bristol-Myers Squibb
- 6.4.1 Bristol-Myers Squibb Company Information
- 6.4.2 Bristol-Myers Squibb Business Overview
- 6.4.3 Bristol-Myers Squibb Pulmonary Embolism Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Bristol-Myers Squibb Pulmonary Embolism Therapeutics Product Portfolio
- 6.4.5 Bristol-Myers Squibb Recent Developments
- 6.5 Boehringer Ingelheim International
- 6.5.1 Boehringer Ingelheim International Company Information
- 6.5.2 Boehringer Ingelheim International Business Overview
- 6.5.3 Boehringer Ingelheim International Pulmonary Embolism Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Boehringer Ingelheim International Pulmonary Embolism Therapeutics Product Portfolio
- 6.5.5 Boehringer Ingelheim International Recent Developments
7 North America
- 7.1 North America Pulmonary Embolism Therapeutics Market Size (2021-2032)
- 7.2 North America Pulmonary Embolism Therapeutics Market Size by Type
- 7.2.1 North America Pulmonary Embolism Therapeutics Market Size by Type (2021-2026)
- 7.2.2 North America Pulmonary Embolism Therapeutics Market Size by Type (2027-2032)
- 7.2.3 North America Pulmonary Embolism Therapeutics Market Share by Type (2021-2032)
- 7.3 North America Pulmonary Embolism Therapeutics Market Size by Application
- 7.3.1 North America Pulmonary Embolism Therapeutics Market Size by Application (2021-2026)
- 7.3.2 North America Pulmonary Embolism Therapeutics Market Size by Application (2027-2032)
- 7.3.3 North America Pulmonary Embolism Therapeutics Market Share by Application (2021-2032)
- 7.4 North America Pulmonary Embolism Therapeutics Market Size by Country
- 7.4.1 North America Pulmonary Embolism Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Pulmonary Embolism Therapeutics Market Size by Country (2021-2026)
- 7.4.3 North America Pulmonary Embolism Therapeutics Market Size by Country (2027-2032)
- 7.4.4 North America Pulmonary Embolism Therapeutics Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Pulmonary Embolism Therapeutics Market Size (2021-2032)
- 8.2 Europe Pulmonary Embolism Therapeutics Market Size by Type
- 8.2.1 Europe Pulmonary Embolism Therapeutics Market Size by Type (2021-2026)
- 8.2.2 Europe Pulmonary Embolism Therapeutics Market Size by Type (2027-2032)
- 8.2.3 Europe Pulmonary Embolism Therapeutics Market Share by Type (2021-2032)
- 8.3 Europe Pulmonary Embolism Therapeutics Market Size by Application
- 8.3.1 Europe Pulmonary Embolism Therapeutics Market Size by Application (2021-2026)
- 8.3.2 Europe Pulmonary Embolism Therapeutics Market Size by Application (2027-2032)
- 8.3.3 Europe Pulmonary Embolism Therapeutics Market Share by Application (2021-2032)
- 8.4 Europe Pulmonary Embolism Therapeutics Market Size by Country
- 8.4.1 Europe Pulmonary Embolism Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Pulmonary Embolism Therapeutics Market Size by Country (2021-2026)
- 8.4.3 Europe Pulmonary Embolism Therapeutics Market Size by Country (2027-2032)
- 8.4.4 Europe Pulmonary Embolism Therapeutics Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Pulmonary Embolism Therapeutics Market Size (2021-2032)
- 9.2 China Pulmonary Embolism Therapeutics Market Size by Type
- 9.2.1 China Pulmonary Embolism Therapeutics Market Size by Type (2021-2026)
- 9.2.2 China Pulmonary Embolism Therapeutics Market Size by Type (2027-2032)
- 9.2.3 China Pulmonary Embolism Therapeutics Market Share by Type (2021-2032)
- 9.3 China Pulmonary Embolism Therapeutics Market Size by Application
- 9.3.1 China Pulmonary Embolism Therapeutics Market Size by Application (2021-2026)
- 9.3.2 China Pulmonary Embolism Therapeutics Market Size by Application (2027-2032)
- 9.3.3 China Pulmonary Embolism Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Pulmonary Embolism Therapeutics Market Size (2021-2032)
- 10.2 Asia Pulmonary Embolism Therapeutics Market Size by Type
- 10.2.1 Asia Pulmonary Embolism Therapeutics Market Size by Type (2021-2026)
- 10.2.2 Asia Pulmonary Embolism Therapeutics Market Size by Type (2027-2032)
- 10.2.3 Asia Pulmonary Embolism Therapeutics Market Share by Type (2021-2032)
- 10.3 Asia Pulmonary Embolism Therapeutics Market Size by Application
- 10.3.1 Asia Pulmonary Embolism Therapeutics Market Size by Application (2021-2026)
- 10.3.2 Asia Pulmonary Embolism Therapeutics Market Size by Application (2027-2032)
- 10.3.3 Asia Pulmonary Embolism Therapeutics Market Share by Application (2021-2032)
- 10.4 Asia Pulmonary Embolism Therapeutics Market Size by Country
- 10.4.1 Asia Pulmonary Embolism Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Pulmonary Embolism Therapeutics Market Size by Country (2021-2026)
- 10.4.3 Asia Pulmonary Embolism Therapeutics Market Size by Country (2027-2032)
- 10.4.4 Asia Pulmonary Embolism Therapeutics Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Pulmonary Embolism Therapeutics Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Pulmonary Embolism Therapeutics Market Size by Type
- 11.2.1 South America, Middle East & Africa Pulmonary Embolism Therapeutics Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Pulmonary Embolism Therapeutics Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Pulmonary Embolism Therapeutics Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Pulmonary Embolism Therapeutics Market Size by Application
- 11.3.1 South America, Middle East & Africa Pulmonary Embolism Therapeutics Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Pulmonary Embolism Therapeutics Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Pulmonary Embolism Therapeutics Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Pulmonary Embolism Therapeutics Market Size by Country
- 11.4.1 South America, Middle East & Africa Pulmonary Embolism Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Pulmonary Embolism Therapeutics Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Pulmonary Embolism Therapeutics Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Pulmonary Embolism Therapeutics Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst